The findings suggest that disease-associated microbes can actively drive intestinal inflammation by reshaping host metabolism, suggesting new therapeutic possibilities to prevent or disrupt diseases like infectious diarrhea and colorectal cancer.

The findings suggest the gut microbiota — microorganisms that live in the intestines — could be a therapeutic target to prevent hospital-acquired lung infections.

One immune cell signaling molecule was increased in active versus inactive Crohn’s disease in both endoscopic and histologic activity assessments, suggesting it could serve as a potential noninvasive marker of disease activity.

The Berry Family Foundation has pledged $1.5 million to the Department of Biostatistics to support improvements to REDCap, a web-based software platform for managing surveys and databases.

The annual event supports vital programs and family resources at Monroe Carell Jr. Children’s Hospital at Vanderbilt.

Study findings suggest a new therapeutic approach for a rare digestive disorder, microvillus inclusion disease.